FR11C0020I1 - - Google Patents

Info

Publication number
FR11C0020I1
FR11C0020I1 FR11C0020C FR11C0020I1 FR 11C0020 I1 FR11C0020 I1 FR 11C0020I1 FR 11C0020 C FR11C0020 C FR 11C0020C FR 11C0020 I1 FR11C0020 I1 FR 11C0020I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27301396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0020(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR11C0020I1 publication Critical patent/FR11C0020I1/fr
Application granted granted Critical
Publication of FR11C0020I2 publication Critical patent/FR11C0020I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
FR11C0020C 1996-12-26 2011-06-21 Dérives difluoroprostaglandines et leur application Active FR11C0020I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP34861496 1996-12-26
JP7405497 1997-03-26
JP17247797 1997-06-27

Publications (2)

Publication Number Publication Date
FR11C0020I1 true FR11C0020I1 (enExample) 2011-07-29
FR11C0020I2 FR11C0020I2 (fr) 2012-03-16

Family

ID=27301396

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0020C Active FR11C0020I2 (fr) 1996-12-26 2011-06-21 Dérives difluoroprostaglandines et leur application

Country Status (16)

Country Link
US (2) US5886035A (enExample)
EP (1) EP0850926B1 (enExample)
JP (2) JP3480549B2 (enExample)
KR (1) KR100526282B1 (enExample)
CN (1) CN1108289C (enExample)
AT (1) ATE225770T1 (enExample)
CA (1) CA2225761C (enExample)
DE (2) DE69716226T2 (enExample)
DK (1) DK0850926T3 (enExample)
ES (1) ES2187719T3 (enExample)
FR (1) FR11C0020I2 (enExample)
LU (1) LU91943I2 (enExample)
NL (1) NL300407I2 (enExample)
NO (2) NO317060B1 (enExample)
PT (1) PT850926E (enExample)
TW (1) TW536534B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE221048T1 (de) * 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
IL134241A (en) * 2000-01-27 2006-06-11 Finetech Pharmaceutical Ltd Process for the preparation of latanoprost
IL143477A (en) 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
WO2001055102A1 (fr) * 2000-01-28 2001-08-02 Asahi Glass Company, Limited Nouveau derive difluoroprostaglandine
EP1321144B1 (en) * 2000-09-13 2010-12-08 Santen Pharmaceutical Co., Ltd. Eye drops
US20050228048A1 (en) * 2002-08-23 2005-10-13 Santen Pharmaceutical Co., Ltd. Stable eye drops containing latanoprost as the active ingredient
EP1547599B1 (en) 2002-09-09 2017-11-01 Santen Pharmaceutical Co., Ltd. Transparent eye drops containing latanoprost
US20060199863A1 (en) * 2003-07-31 2006-09-07 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin
EP2247068B1 (en) * 2003-12-08 2013-09-25 Qualcomm Incorporated High data rate interface with improved link synchronization
CN102526064A (zh) * 2004-12-09 2012-07-04 参天制药株式会社 含有分子内具有氟原子的前列腺素的制品
JP4753178B2 (ja) * 2004-12-24 2011-08-24 参天製薬株式会社 プロスタグランジンＦ２α誘導体含有製品
JP5100025B2 (ja) * 2005-03-31 2012-12-19 旭硝子株式会社 プロスタグランジンＦ２α誘導体を有効成分として含む網膜神経細胞保護剤
SI1864666T1 (sl) * 2005-03-31 2012-10-30 Asahi Glass Co Ltd Zaščitno sredstvo za retinalno nevronsko celico, vsebujoče derivat prostaglandina F2 alfa kot učinkovino
WO2006112313A1 (ja) 2005-04-13 2006-10-26 Ube Industries, Ltd. インダゾール誘導体を有効成分として含む網膜神経細胞保護剤
CA2613010A1 (en) * 2005-06-29 2007-01-04 Pfizer Inc. Fluoroprostaglandins nitroderivatives
JP4851467B2 (ja) * 2006-02-07 2012-01-11 株式会社アールテック・ウエノ プロスタグランジン誘導体の製造法
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
FR2918891B1 (fr) * 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
BRPI0918244A2 (pt) * 2008-09-04 2015-12-15 Santen Pharmaceutical Co Ltd E Asahi Glass Company Ltd agente promotor do crescimento de pelos, e método para prevenir ou tratar uma doença associada com os cabelos.
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
EP2600825B1 (en) 2010-08-02 2018-12-12 Ac Patent Holding Inc. Method for curling hair
EP3378480A1 (en) 2011-01-19 2018-09-26 Topokine Therapeutics, Inc. Methods and compositions for treating obesity
CN103338772A (zh) 2011-02-04 2013-10-02 兴和株式会社 用于预防或治疗青光眼的药物疗法
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
US20150011755A1 (en) * 2012-02-07 2015-01-08 Dr. Reddys Laboratories Limited Amine salts of prostaglandin analogs
CA2874288A1 (en) 2012-05-30 2013-12-05 Asahi Glass Company, Limited Composition for hair growth
CN104936595A (zh) 2012-11-21 2015-09-23 托普凯恩制药公司 局部增加体脂肪的方法和组合物
NO2753788T3 (enExample) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
CN103570549B (zh) * 2013-10-11 2016-01-27 天泽恩源（天津）制药有限公司 一种合成他氟前列素的方法
CN103804195B (zh) * 2014-01-26 2016-06-15 天泽恩源（天津）制药有限公司 一种合成他氟前列素的方法
CN103819436A (zh) * 2014-02-21 2014-05-28 天泽恩源（天津）医药技术有限公司 (3aR,4R,5R,6aS)-4-((E)-3,3-二氟-4-苯氧基丁-1-烯-1-基)-2-氧代六氢-2H-环戊烷[b]呋喃-5-基苯甲酸酯的一种晶型及相应晶体的制备方法
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
KR20160116402A (ko) 2015-03-30 2016-10-10 연성정밀화학(주) 타플루프로스트의 제조방법
KR20180058758A (ko) 2015-09-22 2018-06-01 그레이버그 비젼, 인크. 안구 장애의 치료를 위한 화합물 및 조성물
CN107226790A (zh) * 2016-03-25 2017-10-03 苏州朗科生物技术有限公司 一种高纯度他氟前列素及其类似化合物的制备方法及中间体化合物
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
CN108299192A (zh) * 2017-01-10 2018-07-20 江苏恒瑞医药股份有限公司 一种他氟前列素酸的金属盐化合物结晶形式及其制备方法
CN106986766B (zh) * 2017-05-08 2021-01-12 扬子江药业集团有限公司 他氟前列素的制备方法
CN112457277B (zh) * 2020-12-16 2022-06-28 西安国康瑞金制药有限公司 一种他氟前列腺素的制备方法
CN115322095A (zh) * 2021-01-27 2022-11-11 Ａｇｃ株式会社 他氟前列素的纯化方法
CN112832150B (zh) * 2021-01-27 2022-06-24 中交第三公路工程局有限公司 一种涵洞通道等立面垂直凿毛装置
CN116120268A (zh) * 2023-03-06 2023-05-16 南京华威医药科技集团有限公司 一种他氟前列素中间体杂质及其制备方法
CN116425707A (zh) * 2023-03-31 2023-07-14 南京华威医药科技集团有限公司 一种他氟前列素中间体异构体杂质及其制备方法
CN117024324A (zh) * 2023-08-03 2023-11-10 南京华威医药科技集团有限公司 一种他氟前列素对映异构体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH0770054A (ja) * 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
ATE221048T1 (de) * 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
DE69705421T2 (de) * 1996-11-12 2002-05-16 Alcon Laboratories, Inc. 15-fluoro-prostaglandine als augendrucksenkende mittel

Also Published As

Publication number Publication date
PT850926E (pt) 2003-02-28
KR19980064718A (ko) 1998-10-07
CN1108289C (zh) 2003-05-14
TW536534B (en) 2003-06-11
DE122008000050I2 (de) 2011-06-16
JP3480549B2 (ja) 2003-12-22
LU91943I2 (fr) 2012-04-16
EP0850926B1 (en) 2002-10-09
ES2187719T3 (es) 2003-06-16
NO976085D0 (no) 1997-12-23
US5886035A (en) 1999-03-23
JPH1171344A (ja) 1999-03-16
DK0850926T3 (da) 2003-02-17
NO2009006I2 (no) 2012-03-05
US5985920A (en) 1999-11-16
CA2225761A1 (en) 1998-06-26
DE69716226T2 (de) 2003-06-05
DE122008000050I1 (de) 2009-01-29
NL300407I2 (nl) 2010-03-01
FR11C0020I2 (fr) 2012-03-16
EP0850926A2 (en) 1998-07-01
EP0850926A3 (en) 1999-06-16
CA2225761C (en) 2009-04-21
NL300407I1 (nl) 2009-11-02
KR100526282B1 (ko) 2006-05-17
NO317060B1 (no) 2004-08-02
DE69716226D1 (de) 2002-11-14
ATE225770T1 (de) 2002-10-15
JP2004002462A (ja) 2004-01-08
JP3994074B2 (ja) 2007-10-17
NO976085L (no) 1998-06-29
NO2009006I1 (no) 2009-03-16
CN1187486A (zh) 1998-07-15

Similar Documents

Publication Publication Date Title
FR11C0020I1 (enExample)
IN191779B (enExample)
IN186424B (enExample)
IN190220B (enExample)
IN189571B (enExample)
ITMI960668A0 (enExample)
IN190924B (enExample)
BR7601346U (enExample)
ITMI960474V0 (enExample)
IN188086B (enExample)
IN186846B (enExample)
CN3044347S (enExample)
CN3044168S (enExample)
EP0896385A4 (enExample)
CN3045911S (enExample)
CN3045888S (enExample)
CN3045880S (enExample)
CN3045853S (enExample)
CN3045806S (enExample)
CN3045694S (enExample)
CN3045530S (enExample)
CN3045208S (enExample)
CN3044349S (enExample)
CN3044348S (enExample)
CN3044174S (enExample)